Loading...
Loading...
- Roche Holdings AG RHHBY posted Q1 sales of CHF 14.9 billion, up 3% Y/Y on a constant currency basis and down 1% on a reported basis.
- Sales in the Pharmaceuticals Division decreased 9% to CHF 10.6 billion, hit by biosimilars competition, which cut CHF 1.6 billion from revenue.
- The pandemic continued to negatively impact Pharmaceuticals sales, especially for medicines where regular visits to hospitals or health practices are needed.
- It was partly offset by a 22% increase in Actemra/RoActemra sales used for treating patients with severe COVID-19-associated pneumonia.
- The company posted a 55% increase to CHF 4.3 billion in diagnostic sales in Q1 thanks to strong demand for COVID-19 tests, including a new product to monitor virus mutations.
- Roche affirmed its 2021 outlook, forecasting an increase in sales in the low-to-mid single-digit range, with core EPS growing roughly in line with sales. The company intends to increase its dividend.
- Roche has cut some of its experimental lung drugs from its pipeline, including two mid-stage COVID-19 candidates, the company said in its Q1 Earnings Presentation.
- The first drug, an Amgen-licensed anti-ST2 antibody RG6149, where the trial was started last year and slated to end in January; presumably, the results were not good, and it has been “removed from phase 2.”
- Another COVID-19 asset, RG7880, was also “removed from phase 2.” Both were hoping to stop disease progression in patients with severe pneumonia from COVID.
- The company did have better news on a different antiviral approach, with a phase 3 test of its oral COVID-19 antiviral AT-527 slated to start in Q2.
- It also cut two Phase 1 asthma prospects: RG6151 and RG6244.
- Price Action: RHHBY shares closed 0.6% lower at $42.02 on Tuesday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in